Condition
Blasts 5 Percent or More of Bone Marrow Nucleated Cells
Total Trials
4
Recruiting
0
Active
0
Completed
1
Success Rate
33.3%-53% vs avg
Key Insights
Highlights
Success Rate
33% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
50.0%
2 terminated out of 4 trials
Success Rate
33.3%
-53.2% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
33% success
Data Visualizations
Phase Distribution
4Total
P 1 (4)
Trial Status
Terminated2
Completed1
Withdrawn1
Trial Success Rate
33.3%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT03698552Phase 1TerminatedPrimary
ADCT-602 in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia
NCT02529813Phase 1Completed
CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies
NCT03851081Phase 1Withdrawn
Inotuzumab Ozogamicin and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia
NCT03519984Phase 1Terminated
EphB4-HSA Fusion Protein and Cytarabine /or Liposomal Vincristine in Patients With Recurrent or Refractory Acute Leukemia
Showing all 4 trials